Table 3 Mean change from baseline (week 0) and endpoint (week 12) of primary outcome measures in three groups of patients (mean ± SD), mean difference between groups and effect size (ES, d _Cohen , g _Hedges ) for mean changes from baseline of groups vs placebo group (95% CI), http://www.psychometrica.de/effect_size.html#anova

WOMAC osteoarthritis total Index

7.38 ± 10.02*

6.34 ± 11.38

−5.12

−4.08

−24.84 ^$

−17.18 ^$

ES

0.50

0.37

P < 0.05*

P > 0.05

WOMAC joint pain index

2.02 ± 2.93*

1.86 ± 2.95

−1.32

−1.167

P < 0.05*

P > 0.05

ES

0.47

0.41

WOMAC morning stiffness index

0.46 ± 1.35

0.40 ± 1.54

−12.43 ^$

−9.12 ^$

P > 0.05

P > 0.05

ES

0.22

0.17

WOMAC limitation of physical function index

4.61 ± 6.66

3.83 ± 7.56

−3.27

−2.49

P > 0.05

P > 0.05

ES

0.48

0.34

Chair Stand Test Score

1.74 ± 2.18*

1.87 ± 2.41**

1.30

1.44

P < 0.05*

P < 0.01**

ES

0.51

0.53

Fast Paced Walk Test Speed, m/s.

0.10 ± 0.18**

0.08 ± 0.05*

0.12

0.10

P < 0.01**

P < 0.05*

ES

0.45

0.44

Time up and go test, sec.

1.56 ± 2.04**

0.78 ± 1.98

−1.39

−0.59

P < 0.01**

P > 0.05

ES

0.89

0.40

Stair Climb Test, sec.

2.03 ± 3.60**

1.66 ± 2.37

−1.82

−0.95

P < 0.01**

P > 0.05

ES

0.56

0.55

Blood test 1: ESR

−2.75 ± 0.77

−4.12 ± 0.88

16.63^$

p > 0.05

−7.09^$

p > 0.05

Blood test 2: CRP

−0.787 ± 0.33

−1.274 ± 0.35

18.28^$

p > 0.05

−8.67^$

p > 0.05